Takeda Pharmaceutical Co. has experienced various fluctuations, with stumbles causing significant stock falls on certain days. Despite this, some consider Takeda among the top low-priced Pharma stocks to invest in. The company's relative strength has been soaring, and has increased its dividend distribution to ¥100.00. Positive phase 3 trials results for a narcolepsy drug have been announced, boosting stock prices. However, amid these advances, CEO Christophe Weber has decided to step down after a significant drop in company shares. Global and Asian Pharma stocks have tumbled following President Trump's imminent tariff action and vow to reduce U.S drug prices. Still, Takeda's positives and negatives seem to counterbalance each other. A strong year for the company suggests a continued rise in dividends, and an investment five years ago would have yielded a 42% return. Takeda also issued $2.4 Billion in Guaranteed Notes, indicating a solid financial position. Despite these positives, potential investors should note the company's high dividend yield may hide pitfalls, especially for US investors.
Takeda Pharmaceutical Stocks News Analytics from Mon, 09 Jan 2017 08:00:00 GMT to Wed, 30 Jul 2025 20:04:11 GMT -
Rating 6
- Innovation 4
- Information 8
- Rumor -1
